ALK and cancer: Although the driver mutations including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) have revolutionized the treatment and prognosis of NSCLC, it just focused on the cancer cell intrinsic properties [5, 6].